577 related articles for article (PubMed ID: 26285815)
1. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
2. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Moura MM; Cavaco BM; Pinto AE; Leite V
J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
[TBL] [Abstract][Full Text] [Related]
4. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
5. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
6. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
[TBL] [Abstract][Full Text] [Related]
7. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
Agrawal N; Jiao Y; Sausen M; Leary R; Bettegowda C; Roberts NJ; Bhan S; Ho AS; Khan Z; Bishop J; Westra WH; Wood LD; Hruban RH; Tufano RP; Robinson B; Dralle H; Toledo SP; Toledo RA; Morris LG; Ghossein RA; Fagin JA; Chan TA; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Nelkin BD; Ball DW
J Clin Endocrinol Metab; 2013 Feb; 98(2):E364-9. PubMed ID: 23264394
[TBL] [Abstract][Full Text] [Related]
8. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
Barletta JA; Nosé V; Sadow PM
Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
[TBL] [Abstract][Full Text] [Related]
9. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
[TBL] [Abstract][Full Text] [Related]
11. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
[TBL] [Abstract][Full Text] [Related]
12. Analysis of inherited genetic variants in ret proto-oncogene of Brazilian patients with apparently sporadic medullary thyroid carcinoma.
Guerrero IM; Pessoa CH; Olmedo DB; Pontes ER; Matos LC; Tilli TM; Barcinski MA; Gimba ER
Thyroid; 2006 Jan; 16(1):9-15. PubMed ID: 16487008
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
[TBL] [Abstract][Full Text] [Related]
14. New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma.
Dvoráková S; Václavíková E; Sýkorová V; Dusková J; Vlcek P; Ryska A; Novák Z; Bendlová B
Thyroid; 2006 Mar; 16(3):311-6. PubMed ID: 16571096
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
Cerrato A; De Falco V; Santoro M
J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma.
Magalhães PK; de Castro M; Elias LL; Soares EG; Maciel LM
Thyroid; 2004 Oct; 14(10):848-52. PubMed ID: 15588382
[TBL] [Abstract][Full Text] [Related]
17. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS
Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386
[TBL] [Abstract][Full Text] [Related]
18. Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.
Wei S; LiVolsi VA; Montone KT; Morrissette JJ; Baloch ZW
Endocr Pathol; 2016 Dec; 27(4):359-362. PubMed ID: 27379493
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
